- Home
- TAC vs INDV Comparison
TAC vs INDV Comparison
Compare TAC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | INDV |
|---|---|---|
| Founded | 1909 | N/A |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TAC | INDV |
|---|---|---|
| Price | $13.90 | $40.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.67 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | ★ N/A | $58.70 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $11.38 | $15.00 |
| 52 Week High | $17.88 | $42.81 |
Technical Indicators
Market Signals| Indicator | TAC | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 56.94 |
| Support Level | $13.37 | $38.42 |
| Resistance Level | $14.03 | $41.00 |
| Average True Range (ATR) | 0.41 | 1.55 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 36.69 | 49.79 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).